Injective has staged a strong recovery from its prolonged downtrend, with technical indicators suggesting the market is entering a consolidation phase near key resistance levels. Meanwhile, growing institutional adoption, including the launch of a regulated INJ fund in Asia, is strengthening long-term confidence in the network.
